View printer-friendly version

<<  Back
Patrick Soon-Shiong, MD, to Deliver Cancer Moonshot 2020 Keynote at Biocom Global Life Science Partnering Conference

La Jolla, CA February 24, 2016 –Patrick Soon-Shiong, M.D., founder and CEO of NantWorks, LLC, and leader of the Cancer MoonShot 2020 program, will deliver the keynote session, “Cancer Moonshot 2020 & The National Immunotherapy Coalition,” at the sixth annual Biocom Global Life Science Partnering Conference, an exclusive partnering forum from February 24-25, 2016 at The Lodge at Torrey Pines in La Jolla, California. Biocom will bring together leaders from pharmaceutical and biotech companies to network with from around the globe.

During his keynote, Dr. Soon-Shiong will address the need for exploitation of immunotherapy for the benefit of millions of cancer patients. Session attendees will learn about current breakthroughs in immuno-oncology through the vision of Cancer MoonShot 2020. Dr. Soon-Shiong will also touch on the National Immunotherapy Coalition, a historic arrangement that brings together pharmaceutical, biotechnology, national and regional payers and self-insured Fortune 50 companies, academia and oncology centers to accelerate immunotherapies as the next generation standard of care in patients with cancer.

WHO:              Patrick Soon-Shiong M.D., FRCS(C), FACS, chairman and chief executive officer, NantWorks

WHAT:            Keynote Address: “Cancer MoonShot 2020 & The National Immunotherapy Coalition”

WHEN:            Thursday, February 25, 12:30-1:15 p.m. PST

WHERE:          Biocom Global Life Science Partnering Conference
The Lodge at Torrey Pines
11480 North Torrey Pines Road
La Jolla, CA 85054
Register Here

About Cancer MoonShot 2020
Cancer MoonShot 2020 is the nation’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational moonshot to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit;;esheet=51282126&amp;newsitemid=20160218005678&amp;lan=en-US&amp;;index=1&amp;md5=2d9f9b320c46c8f3c5d9df9e4eabb89a


Press Contact:
Jen Hodson